Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
March 14 2023 - 8:55AM
Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY)
(“Clearmind” or the "company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, today announced the
appointment of Professor Henry R. Kranzler, M.D., as the newest
member of its Scientific Advisory Board ("SAB").
Professor Kranzler is the Benjamin Rush Professor of Psychiatry,
and Director of the Center for Studies of Addiction, at the
University of Pennsylvania’s Perelman School of Medicine, which was
ranked #6 in 2023 on the US News & World Report rankings.
His research focuses on the genetics and pharmacological
treatment of substance dependence, with emphasis on precision
addiction medicine. His research has been continuously
supported since 1987 by grants from the National Institutes of
Health.
"Clearmind’s drug candidates are novel agents that have the
potential to alter substantially the landscape of alcohol and other
substance use disorder treatment,” said Professor Kranzler, “The
company’s forward-looking approach to medications development
promises to yield important new discoveries.”
Professor Kranzler has authored or co-authored more than 600
journal articles, book chapters, and books, is a member of the
editorial board of three peer-review journals as well as the
editor of Alcohol: Clinical and Experimental Research. His work
currently focuses on the molecular genetics of substance dependence
and the personalized treatment of alcohol, opioid, and nicotine use
disorders using a pharmacogenetic approach.
“We are honored to have a world-renowned figure like Professor
Kranzler join our SAB alongside other prestigious professionals,"
said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer.
“Professor Kranzler is an expert on addiction medicine, especially
genetic and pharmacological aspects of alcohol and other substance
use disorders, aligning perfectly with Clearmind's mission. We are
thrilled and look forward to his contributions to Clearmind’s
beneficial work given his stature, vast knowledge and expertise in
the addiction field.”
About Clearmind
Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The company’s intellectual portfolio currently consists of 13
patent families. The company intends to seek additional patents for
its compounds whenever warranted and will remain opportunistic
regarding the acquisition of additional intellectual property to
build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY”.
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relationsinvest@clearmindmedicine.comTelephone: (604)
260-1566General InquiriesInfo@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. Forward-looking statements are not
historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. In addition, we cannot assure that any patent will
issue as a result of a pending patent application or, if issued,
whether it will issue in a form that will be advantageous to us.
Forward-looking statements are subject to risks and uncertainties
that could cause actual performance or results to differ materially
from those expressed in the forward-looking statements. For a more
detailed description of the risks and uncertainties affecting the
Company, reference is made to the Company’s reports filed from time
to time with the Securities and Exchange Commission (“SEC”),
including, but not limited to, the risks detailed in the Company’s
annual report on Form 20-F filed with the SEC on February 6, 2023.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party
websites.
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Apr 2023 to Apr 2024